Effectiveness and Tolerance of Multi-Corrective Topical Treatment for Infraorbital Dark Circles and Puffiness

Treatment of infraorbital dark circles and under-eye puffiness is challenging due to its multifactorial nature and lack of broadly applicable, effective treatments. A daily skincare treatment option that is multi-modal, effective, and tolerable across a broad patient population is an unmet need. A multi-corrective topical eye cream (MTEC) formulated with Tetrahexyldecyl (THD) ascorbate (vitamin C), prebiotic Inula Helenium , bioavailable peptides, botanical extracts, chrysin, and caffeine, is hypothesized to improve the appearance of infraorbital dark circles and under-eye puffiness by targeting micro-vasculature congestion and permeability, melanin accumulation and hemoglobin degradation related pigmentation, and skin health. An IRB approved, open-label, 12-week clinical study set out to evaluate the efficacy and tolerability of the MTEC across a broad patient population including varying ethnicities and Fitzpatrick Skin Types (FST). Female subjects (n = 40) ages 35 to 60 years old, with moderate to severe under-eye dark circles, moderate under-eye puffiness, and mild-to-moderate fine lines were enrolled into the study. Objective (Chromameter, VISIA ® imaging, and Laser Doppler) and subjective assessments (clinical grading and self-assessment questionnaire) were conducted at baseline and post-baseline timepoints. The MTEC efficaciously demonstrated short-term and long-term improvements in objective and subjective assessments across a broad patient population. Specifically, the MTEC demonstrated significant improvement of infraorbital dark circles, mainly by the reduction of micro-vasculature congestion and permeability, melanin and hemoglobin degradation related pigmentation. Topical application of the MTEC may offer an effective and tolerable treatment option for infraorbital dark circles and puffiness.